| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Halfan | GlaxoSmithkline | Surgipharm Ltd | 250mg | 6 | Tablet | per tablet | KES 799.10 |
| Halfan | GlaxoSmithkline | Surgipharm Ltd | 100mg | 30ml | Suspension | per 5ML | KES 527.70 |
| Halofantrine More info | |
|---|---|
| Mode Of Action | May inhibit meroThey are also thought to inhibit heme polymerase activity resulting in accumulation of free heme, which is toxic to the parasites. |
| Drug Indication | Acute P. falciparum and P. vivax. |
| Precautions | Excreted in milk, prolonged QTC interval, not used in cerebral malaria in com-bination with other medicine or clinical conditions, which prolong QTC interval, or patient with ventricular dysrrythmias. Consider ECG to exclude above conditions. Renal and hepatic impairment, evidence of increased CNS side effects when associated with either therapeutic or prophylactic use of chloroquine or sulphadoxine / pyrimethamine. |
| Contra-Indications | |
| Side Effects | Skin rashes, pruritus, GI disturbances, severe ventricular dysrrhythmias that may be associated with death, this risk is increased by the use of high doses or concomitant or recent use of mefloquine. AV conduction disorders or unexplained syncopal attacks. |
| Dosage | Over 40kg: 500mg six hourly intervals (to 6 tabs). Under 40kg: 8mg/kg six hourly intervals (to 24mg/kg). For patients with no previous exposure to malaria a second course is repeated after one week. |
| Pregnancy Category | Category C |
| Pregnancy Category Description | Drugs which, owing to their pharmacological effects, or may be suspected of causing detrimental effects on human foetus or neonates without causing malfunctions. These effects may be reversible |
| Drug Category | DRUGS ACTING ON INFECTIONS |
| Drug Sub-Category | Anti-Malarials |